Stuart Gallagher

4.1k citations

51 papers · 3.2k indexed · 2 hit papers · h-index 26

Impact in

Cardiology and Cardiovascular Medicine top 2%
- Cardiovascular Health and Disease Prevention
- Blood Pressure and Hypertension Studies
Physiology top 2%
- Nitric Oxide and Endothelin Effects

Papers in ⓘ

Oncology 23
- Cancer Immunotherapy and Biomarkers 11
- CAR-T cell therapy research 7
Immunology 11
- Immunotherapy and Immune Responses 7

Co-authors: Mark A. Creager (3 shared papers)John P. Cooke (2 shared papers)S. M. Coleman (2 shared papers)Peter Hersey (32 shared papers)Jessamy Tiffen (25 shared papers)J Loscalzo (2 shared papers)M E Mendelsohn (1 shared paper)Victor J. Dzau (1 shared paper)
Journals: Pigment Cell & Melanoma Research (9 papers)Journal of Investigative Dermatology (4 papers)Neoplasia (2 papers)Journal of Clinical Investigation (2 papers)Cancers (2 papers)
Partner nations: Australia United States France

In The Last Decade

Stuart Gallagher

50 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. 1992 · 670 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1992 Journal of Clinical Investigation
1990 Journal of Clinical Investigation

Peers

Countries citing papers authored by Stuart Gallagher

Since Specialization

Citations

This map shows the geographic impact of Stuart Gallagher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Gallagher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Gallagher more than expected).

Fields of papers citing papers by Stuart Gallagher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Gallagher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Gallagher. The network helps show where Stuart Gallagher may publish in the future.

Co-authors

The 25 scholars most cited alongside Stuart Gallagher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stuart Gallagher Line = papers co-authored together Stuart Gallagher links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. Journal of Clinical Investigation ·Mark A. Creager, John P. Cooke, M E Mendelsohn, Stuart Gallagher, S. M. Coleman, J Loscalzo, Victor J. Dzau Hit paper breakdown →	1990	849
2	L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. Journal of Clinical Investigation ·Mark A. Creager, Stuart Gallagher, Xavier Girerd, S. M. Coleman, V J Dzau, John P. Cooke Hit paper breakdown →	1992	670
3	Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB PLoS ONE ·Kavitha Gowrishankar, Dilini Gunatilake, Stuart Gallagher, Jessamy Tiffen, Helen Rizos, Peter Hersey	2015	191
4	Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy Trends in Immunology ·Abdullah Al Emran, Aniruddha Chatterjee, Euan J. Rodger, Jessamy Tiffen, Stuart Gallagher, Michael R. Eccles, Peter Hersey	2019	158
5	Beta-catenin inhibits melanocyte migration but induces melanoma metastasis Oncogene ·Stuart Gallagher, Florian Rambow, Mayuko Y. Kumasaka, Delphine Champeval, Alfonso Bellacosa, Véronique Delmas, Lionel Larue	2012	84
6	Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma iScience ·Aniruddha Chatterjee, Euan J. Rodger, Antonio Ahn, Peter A. Stockwell, Matthew Parry, Jyoti Motwani, Stuart Gallagher, Elena Shklovskaya, Jessamy Tiffen, Michael R. Eccles, Peter Hersey	2018	71
7	Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling Oncotarget ·Anja Heinemann, Carleen Cullinane, Ricardo De Paoli‐Iseppi, James S. Wilmott, Dilini Gunatilake, Jason Madore, Dario Strbenac, Jean Yang, Kavitha Gowrishankar, Jessamy Tiffen, Rab K. Prinjha, Nicholas Smithers, Grant A. McArthur, Peter Hersey, Stuart Gallagher	2015	71
8	Control of NF‐kB activity in human melanoma by bromodomain and extra‐terminal protein inhibitor I‐BET151 Pigment Cell & Melanoma Research ·Stuart Gallagher, Branka Mijatov, Dilini Gunatilake, Kavitha Gowrishankar, Jessamy Tiffen, W. Freeman James, Lei Jin, Gulietta M. Pupo, Carleen Cullinane, Grant A. McArthur, Peter J. Tummino, Helen Rizos, Peter Hersey	2014	70
9	SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling Nature Communications ·Thomas Strub, Flávia G. Ghiraldini, Saul Carcamo, Man Li, Aleksandra Wroblewska, Vikram Singh, Matthew S. Goldberg, Dan Hasson, Zichen Wang, Stuart Gallagher, Peter Hersey, Avi Ma’ayan, Georgina V. Long, Richard A. Scolyer, Brian D. Brown, Bin Zheng, Emily Bernstein	2018	66
10	The ARF tumour suppressor The International Journal of Biochemistry & Cell Biology ·Stuart Gallagher, Richard Kefford, Helen Rizos	2006	64
11	Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes Oncotarget ·Jessamy Tiffen, Dilini Gunatilake, Stuart Gallagher, Kavitha Gowrishankar, Anja Heinemann, Carleen Cullinane, Ken Dutton‐Regester, Gulietta M. Pupo, Dario Strbenac, Jean Yang, Jason Madore, Graham J. Mann, Nicholas K. Hayward, Grant A. McArthur, Fabian V. Filipp, Peter Hersey	2015	62
12	Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report Cancer Immunology Immunotherapy ·Helen M. McGuire, Elena Shklovskaya, Jarem Edwards, Paul Trevillian, Geoffrey W. McCaughan, Patrick Bertolino, Catriona McKenzie, Ralph Gourlay, Stuart Gallagher, Barbara Fazekas de St Groth, Peter Hersey	2017	51
13	The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells Journal of Investigative Dermatology ·Stuart Gallagher, Branka Mijatov, Dilini Gunatilake, Jessamy Tiffen, Kavitha Gowrishankar, Lei Jin, Gulietta M. Pupo, Carleen Cullinane, Rab K. Prinjha, Nicholas Smithers, Grant A. McArthur, Helen Rizos, Peter Hersey	2014	51
14	Epigenetic modulation in cancer immunotherapy Current Opinion in Pharmacology ·Stuart Gallagher, Elena Shklovskaya, Peter Hersey	2017	50
15	EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma Journal of Investigative Dermatology ·Jessamy Tiffen, Stuart Gallagher, Fabian V. Filipp, Dilini Gunatilake, Abdullah Al Emran, Carleen Cullinane, Ken Dutton‐Regester, Lauren G. Aoude, Nicholas K. Hayward, Aniruddha Chatterjee, Euan J. Rodger, Michael R. Eccles, Peter Hersey	2020	49
16	Automated Cell Tracking and Analysis in Phase-Contrast Videos (iTrack4U): Development of Java Software Based on Combined Mean-Shift Processes PLoS ONE ·Fabrice P. Cordelières, Valérie Petit, Mayuko Y. Kumasaka, Olivier Debeir, Véronique Letort, Stuart Gallagher, Lionel Larue	2013	49
17	The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance Carcinogenesis ·David Wroblewski, Branka Mijatov, Nethia Mohana‐Kumaran, Fritz Lai, Stuart Gallagher, Nikolas K. Haass, Xu Dong Zhang, Peter Hersey	2012	47
18	Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors Advances in pharmacology ·Fritz Lai, Lei Jin, Stuart Gallagher, Branka Mijatov, Xu Dong Zhang, Peter Hersey	2012	46
19	EZH2: an emerging role in melanoma biology and strategies for targeted therapy Pigment Cell & Melanoma Research ·Jessamy Tiffen, Stuart Gallagher, Peter Hersey	2014	44
20	Intralesional immunotherapy for melanoma Journal of Surgical Oncology ·Peter Hersey, Stuart Gallagher	2013	41

About Stuart Gallagher

Stuart Gallagher is a scholar working on Oncology, Immunology, Molecular Biology, Cell Biology and Biophysics, having authored 51 papers that have together received 3.2k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (14 papers), Melanoma and MAPK Pathways (11 papers), Cancer Immunotherapy and Biomarkers (11 papers), Protein Degradation and Inhibitors (10 papers), Epigenetics and DNA Methylation (10 papers), Immunotherapy and Immune Responses (7 papers), CAR-T cell therapy research (7 papers) and Ubiquitin and proteasome pathways (6 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (942 citations), Physiology (875 citations), Biochemistry (201 citations), Oncology (688 citations) and Immunology (517 citations). Stuart Gallagher has collaborated with scholars based in Australia, United States and France. Frequent co-authors include Mark A. Creager, John P. Cooke, S. M. Coleman, Peter Hersey, Jessamy Tiffen, J Loscalzo, M E Mendelsohn, Victor J. Dzau, V J Dzau and Xavier Girerd. Their work appears in journals such as Pigment Cell & Melanoma Research, Journal of Investigative Dermatology, Neoplasia, Journal of Clinical Investigation and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact